

We claim:

- 1) A crystalline aripiprazole form III, characterized by an x-ray powder diffraction spectrum having peaks expressed as  $2\theta$  at about 8.8, 11.2, 11.4, 11.9, 13.6, 14.4, 15.0, 15.9, 16.4, 17.8, 18.7, 20.4, 20.8, 21.4, 22.2, 23.5, 25.0, 25.9 and 26.5 degrees.
- 5 2) A crystalline aripiprazole form III as defined in claim 1, further characterized by an x-ray powder diffraction spectrum as in figure 1.
- 3) A process for preparation of aripiprazole form III as defined in claim 1, which comprises the steps of:
  - 10 a) preparing a solution of aripiprazole in a mixture of methyl tert-butyl ether, acetonitrile and tetrahydrofuran; and
  - b) isolating aripiprazole form III from the solution.
- 4) Aripiprazole methanolate.
- 5) Aripiprazole methanolate of claim 4, wherein methanol content is between about 2 to 6% of the weight of aripiprazole methanolate.
- 15 6) A crystalline aripiprazole methanolate form IV, characterized by an x-ray powder diffraction spectrum having peaks expressed as  $2\theta$  at about 9.8, 11.0, 11.8, 12.1, 12.6, 13.6, 17.4, 18.8, 20.1, 23.3, 24.6, 25.0, 25.9, 27.2, 28.4, 29.3, 30.1 and 31.5 degrees.
- 20 7) A crystalline aripiprazole methanolate form IV as defined in claim 6, further characterized by an x-ray powder diffraction spectrum as in figure 2.
- 8) A process for preparation of aripiprazole methanolate as defined in claim 4, which comprises the steps of:
  - 25 a) preparing a solution of aripiprazole in a mixture of methanol and tetrahydrofuran; and
  - b) isolating aripiprazole methanolate from the solution.
- 9) A process according to claim 8, wherein the product obtained is aripiprazole methanolate.
- 30 10) A process according to claim 3, wherein aripiprazole is used in the form of Aripiprazole methanolate.
- 11) Aripiprazole ethylenedichloride solvate.
- 12) Aripiprazole ethylenedichloride solvate of claim 11, wherein ethylenedichloride content is between about 15 to 40% of the weight of aripiprazole ethylenedichloride solvate.

13) A crystalline aripiprazole ethylenedichloride solvate form V, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 10.7, 17.6, 17.8, 20.6, 22.1, 23.4, 24.7 and 26.4 degrees.

14) A crystalline aripiprazole ethylenedichloride solvate form V as defined in claim 13, further characterized by an x-ray powder diffraction spectrum as in figure 3.

15) A process for preparation of aripiprazole ethylenedichloride solvate as defined in claim 11, which comprises the steps of:

a) preparing a solution of aripiprazole in ethylenedichloride; and

b) isolating aripiprazole ethylenedichloride solvate from the solution.

16) A process according to claim 15, wherein the product obtained is aripiprazole ethylenedichloride form V.

17) A process according to claim 3, wherein aripiprazole used is in the form of Aripiprazole ethylenedichloride.

18) A pharmaceutical composition comprising aripiprazole form III of claim 1 and a pharmaceutically acceptable carrier or diluent.

20